347 related articles for article (PubMed ID: 27856777)
21. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
22. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
[No Abstract] [Full Text] [Related]
23. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
Navardi S; Sahraian MA
Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
[TBL] [Abstract][Full Text] [Related]
24. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
[No Abstract] [Full Text] [Related]
25. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
Hovi A; Airas L
J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
[No Abstract] [Full Text] [Related]
26. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
27. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
[TBL] [Abstract][Full Text] [Related]
28. Early and recurrent macular oedema in a patient treated with fingolimod.
Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
[No Abstract] [Full Text] [Related]
29. Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
Kraemer M; Weber R; Herold M; Berlit P
Mult Scler; 2015 Oct; 21(11):1473-5. PubMed ID: 26283695
[TBL] [Abstract][Full Text] [Related]
30. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
[TBL] [Abstract][Full Text] [Related]
31. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
32. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Zięba N; Gębka-Kępińska B; Sowa P
Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
[TBL] [Abstract][Full Text] [Related]
33. Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
Müller-Jensen L; Kriedemann H; Anvari K; Huehnchen P; Siffrin V
Neurology; 2023 Apr; 100(14):670-671. PubMed ID: 36539295
[TBL] [Abstract][Full Text] [Related]
34. Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.
Cellerino M; Bonavita S; Ferrero M; Inglese M; Boffa G
J Neurol Sci; 2020 Nov; 418():117156. PubMed ID: 33010653
[No Abstract] [Full Text] [Related]
35. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
36. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous Merkel cell carcinoma: multiple asynchronous primary lesions in a patient on immunosuppressive therapy.
Sparks J; Sparks M; Malone JC
J Cutan Pathol; 2017 Mar; 44(3):309-312. PubMed ID: 27990669
[No Abstract] [Full Text] [Related]
38. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
39. Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
Baghbanian SM; Amiri MRM
Neurol Sci; 2021 Mar; 42(3):1175-1177. PubMed ID: 32968870
[No Abstract] [Full Text] [Related]
40. Treatment-refractory warts associated with fingolimod.
Sahi N; Al-Araji SA; Ciccarelli O; Chard DT; Trip SA
Pract Neurol; 2022 Dec; 22(6):503-504. PubMed ID: 35981859
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]